—
C+
C+ The full Closelooknet — membership. Open the C+ overview

TELIX Pharmaceuticals Ltd (TLX.AU) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for TLX.AU, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against TLX.AU on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — TELIX Pharmaceuticals Ltd

TLX.AU in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Telix Pharmaceuticals develops radiopharmaceuticals, medicines that pair radioactive isotopes with molecules aimed at cancer cells, used for both imaging and treatment. It runs three business lines, precision medicine, therapeutics and manufacturing solutions, and already sells two prostate-cancer imaging agents, Illuccix and Gozellix. Its most advanced treatment candidate is a lutetium-labelled antibody conjugate for advanced prostate cancer, in a late-stage trial, alongside earlier programmes for kidney cancer, brain tumours and bone-marrow conditioning. It is headquartered in Melbourne and operates across several countries including the United States and the United Kingdom.
Where it sits in the stack
Telix carries no seat in Rubin or Halo, our AI-related indices; it sits within the diary's wider healthcare and biotechnology coverage, outside the AI build-out stack the diary otherwise tracks.
Who it is priced against
Closelooknet has no peer group defined for Telix; the market's natural comparison is Novartis, whose radioligand therapy business competes directly in prostate-cancer treatment.
Why Closelooknet tracks it
Telix holds no seat in Rubin or Halo, carries no Closelooknet score, and is not quoted in the diary's editions; it appears only in our routine price readings, without established index coverage.
What the diary watches
The diary watches whether the current pull-back extends below its 50-day average or holds above it, after the stock's recent slide off its high.

TELIX Pharmaceuticals Ltd (TLX.AU) trades on the AU exchange in Australia.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months · buybacks 2 m AUD in FY2025

Dividends and capital return

What TLX.AU pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 2 m AUD 0.0% of today's market value
  • Share count −2.1% in FY2025
  • Capital returned 2 m AUD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is TELIX Pharmaceuticals Ltd (TLX.AU)?

TELIX Pharmaceuticals Ltd trades as TLX.AU on the AU exchange (Australia) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is TLX.AU in a Closelooknet index?

Not currently — TELIX Pharmaceuticals Ltd is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does TLX.AU trade against its moving averages?

Pullback inside an uptrend stack: Trades +0% vs the 50-day and +16.6% vs the 200-day average, 12.7% below the 52-week high and +92.5% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

What does TELIX Pharmaceuticals Ltd do?

Telix Pharmaceuticals develops radiopharmaceuticals, medicines that pair radioactive isotopes with molecules aimed at cancer cells, used for both imaging and treatment. It runs three business lines, precision medicine, therapeutics and manufacturing solutions, and already sells two prostate-cancer imaging agents, Illuccix and Gozellix. Its most advanced treatment candidate is a lutetium-labelled antibody conjugate for advanced prostate cancer, in a late-stage trial, alongside earlier programmes for kidney cancer, brain tumours and bone-marrow conditioning. Closelooknet has no peer group defined for Telix; the market's natural comparison is Novartis, whose radioligand therapy business competes directly in prostate-cancer treatment.

Where does TELIX Pharmaceuticals Ltd sit in the AI build-out?

Telix carries no seat in Rubin or Halo, our AI-related indices; it sits within the diary's wider healthcare and biotechnology coverage, outside the AI build-out stack the diary otherwise tracks. Telix holds no seat in Rubin or Halo, carries no Closelooknet score, and is not quoted in the diary's editions; it appears only in our routine price readings, without established index coverage.

Does TELIX Pharmaceuticals Ltd pay a dividend?

No cash distribution shows in TELIX Pharmaceuticals Ltd’s price series over the last three years. In fiscal 2025 the company bought back 2 m AUD of its own shares. The share count fell 2.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for TLX.AU, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.